Xenetic Biosciences (XBIO) 10-K2019 FY Annual report

Filed: 26 Mar 20, 5:12pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Adam, aggressive, aim, allogeneic, annum, appeal, axicabtagene, billion, biosimilar, Blueprint, borrowing, BPCIA, ceiling, ciloleucel, CMS, Coast, Congressional, coupled, CRS, curative, cytokine, delisted, deregulation, diagnosed, die, differentiated, diffuse, disabled, District, domestic, easier, Eighty, encourage, entertain, entirety, EU, fall, fatal, feedback, follicular, forefront, formulary, FSS, fueled, furniture, genetically, Gilead, graft, Guard, guideline, GvHD, hindsight, hospital, HSCT, identification, implicit, incentivize, increasingly, inflation, inflationary, inherited, injectable, inNote, Inspector, Kymriah, laid, lived, Logal, lymphocytic, lymphoplasmacytic, mantle, military, modality, mortality, nearest, needy, neurologic, NHL, notification, Onthe, outbreak, outpatient, overallotment, passed, penny, pharmacy, pocket, prefunded, presidential, pro, proportionately, rata, refractory, Reg, regained, release, repay, residual, retroactive, ROU, soldpursuant, soliciting, SRC, Statute, sublicensee, substitution, syndrome, takeover, TCR, tech, tender, tisagenlecleucel, Treasurer, TRICARE, unclear, unconstitutional, unfolding, Vice, wecompleted, XBIOW, Yescarta, zone

Removed: acting, Adult, affirmative, aforementioned, allocable, Altered, amend, American, amortization, anniversary, anthracycline, antineoplastic, April, assumption, assured, attempted, biomarker, breast, buyer, calculate, calling, carboplatin, catch, center, characterize, chemotherapeutic, cisplatin, cohort, collectability, compound, copy, cumulative, cytotoxic, Dana, depot, determinable, discharge, dispose, divided, dose, Downstream, doxorubicin, elucidate, Emergent, ER, estrogen, expiry, explanatory, exploratory, exposure, Farber, fifty, greatest, Harvard, Hematology, hemoglobin, ifosfamide, immunomodulatory, insensitive, judged, kinase, knowledge, leased, Ledgemont, Maguire, match, MD, Medicine, minimize, NE, negligible, organizational, pathway, percent, persuasive, PJSC, possession, presently, Professor, promissory, provisional, PulmoXen, ranking, receivable, reconciling, reorganization, restating, restructure, rh, Richard, Room, round, scheduled, School, Scott, Signaling, Simplifying, Society, staffing, standing, Stone, successor, suggest, surviving, Taxol, TEAE, TNBC, topotecan, travel, underwritten, unsolicited, Virexxa, Washington

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

XBIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

We consent to the incorporation by reference in the Registration Statement of Xenetic Biosciences, Inc. on Form S-8 (File Nos. 333-222272 and 333-218024), on Form S-3 (File Nos. 333-227572 and 333-233769) of our report dated March 26, 2020, with respect to our audits of the consolidated financial statements of Xenetic Biosciences, Inc. as of December 31, 2019 and 2018 and for each of the two years in the period ended December 31, 2019, which report is included in this Annual Report on Form 10-K of Xenetic Biosciences, Inc. for the year ended December 31, 2019.

/s/ Marcum LLP

Marcum LLP

Boston, Massachusetts

March 26, 2020